PIK3CA and non-small cell lung carcinoma: The clinical significance lies in the potential of this novel therapeutic approach to overcome the limitations of current treatments, particularly addressing resistance issues caused by PI3K mutations, providing a new treatment option that significantly improves the prognosis and survival rates of NSCLC patients.